Skip to content
Bamboo WorksBamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Weight-loss drug

Innogen Pharma

Innogen Pharma jostles for a slice of the weight-loss market

The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
December 13, 2024
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market.

AstraZeneca pays hefty price for Chinese weight-loss drug

The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
November 23, 2023
AZN.US

Recent Articles

Innogen Pharma
December 13, 2024

Innogen Pharma jostles for a slice of the weight-loss market

November 23, 2023

AstraZeneca pays hefty price for Chinese weight-loss drug

AZN.US

RECENT ARTICLES

  1. 派格生物減肥藥
    November 21, 2024
    PegBio aims to bulk up its finances to deliver weight-loss drugs
  2. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  3. December 5, 2024
    Xuanzhu Biopharm set for spin-off in Hong Kong IPO
    0460.HK
  4. December 19, 2024
    Hengrui Pharma accelerates bid for global brand status
    600276.SHG
  5. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  6. December 12, 2024
    Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.